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摘要
目的:通过评估比较治疗前后解剖结构和视功能的变化,
包括视网膜神经纤维厚度、图形视觉诱发电位、传统视神
经功能检查,早期检测乙胺丁醇毒性。
方法:前瞻性研究,包括参加马来西亚理科大学医院的短
期治疗观察项目的 36 例 72 眼结核病患者。 视力和视神
经功能检查由同一位研究者进行。 同样,Humphrey 自动
视野检查、光学相干断层扫描(OCT)检查视网膜神经纤维
厚度(RNFL)和图形视觉诱发电位(PVEP)均由同一位技
术人员进行。 在开始乙胺丁醇治疗前和治疗 3mo 后各进
行检查一次。
结果:乙胺丁醇治疗前后视力、彩色视觉、光亮度、红光反
射和眼底检查无明显改变。 然而,平均视野缺损在治疗后
较前变差(P = 0. 010)。 OCT 和 PVEP 有显著变化,P100
潜伏期延长、幅度降低,RNFL 在各个象限均增厚 ( P <
0郾 05)。
结论:通过 OCT检测 RNFL厚度以及使用 PVEP检测 P100
波峰潜伏期和幅度,可以在传统视神经功能检查异常之
前,发现乙胺丁醇治疗后早期解剖结构和视功能的亚临床
改变。
关键词:乙胺丁醇毒性;视神经功能;视网膜神经纤维厚
度;光学相干断层扫描;视觉诱发电位
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Abstract
誗AIM: To evaluate if early ethambutol toxicity can be
detected by comparing pre - and post - treatment
anatomical and visual function using retinal nerve fiber
thickness, pattern visual evoked potentials and
conventional optic nerve function tests.
誗METHODS:This was a prospective study involving 72
eyes of 36 patients treated with ethambutol according to
directly observed treatment short-course(DOTS) strategy
in Hospital Universiti Sains Malaysia, Kelantan, Malaysia.
The visual acuity and optic nerve function tests were
performed by a single investigator. Likewise, Humphrey
automated perimetry, optical coherence tomography
(OCT ) measurement of the retinal nerve fibre layer
(RNFL) and pattern visual evoked potential (PVEP) were
performed by a single technician. The examinations were
performed before initiating ethambutol treatment and 3mo
after that.
誗RESULTS: There was no change in visual acuity, colour
vision, light brightness, red saturation and fundus
findings pre and post ethambutol. However, there was a
statistically significant deterioration in the mean deviation
of the visual field post treatment (P = 0. 010) . There were
also significant changes on OCT and PVEP, with increased
RNFL thickness in all quadrants ( P < 0. 05 ) and PVEP
delayed P100 peak latency and amplitude (P<0. 001) .
誗 CONCLUSION: Ethambutol toxicity is a known
complication of tuberculosis treatment. Early detection of
this toxicity may prevent severe irreversible visual loss.
The use of OCT to detect RNFL thickness and PVEP to
assess P100 latency and amplitude can assist in the
detection of subclinical anatomical and visual function
changes prior to development of abnormalities on
conventional optic nerve function tests.
誗KEYWORDS: ethambutol toxicity; optic nerve function;
retinal nerve fiber layer; optical coherence tomography;
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INTRODUCTION
T uberculosis is an endemic disease in most developingcountries, including Malaysia. It is caused by
mycobacterium tuberculosis, which can infect any part of the
body, but mainly affects the lungs.
Ethambutol hydrochloride is used as a first - line drug in the
treatment of tuberculosis, as part of the directly observed
treatment short-course (DOTS) strategy recommended by the
World Health Organization (WHO).
Ethambutol has the potential to cause toxic optic
neuropathy[1] . The incidence of ethambutol toxicity has been
reported to range from 1% to 18% in various studies[2-3] .
Despite the recommended dose of 15 - 20mg / kg perday,
ethambutol toxicity has been found to occur in doses that are
lower than the normal recommended dose[4-5] . There is no
reported safe dose of ethambutol[6] . Although this toxicity has
been considered reversible on discontinuation of the
treatment, there have also been reports of irreversible severe
visual loss despite immediate cessation of ethambutol[1, 6-9] .
Early detection of ocular toxic effects before occurrence of
symptoms may prevent permanent optic nerve damage and
allow complete recovery of normal function[10-11] . However, it
remains to be determined whether early ocular toxicity can be
accurately detected by regular clinical tests like visual acuity,
visual field, colour vision test, light brightness and red
saturation ( optic nerve function tests ) . Optical coherence
tomography (OCT) of the retinal nerve fiber layer (RNFL)
and electrophysiological tests like pattern visual evoked
potential ( PVEP ) have the potential to document subtle
anatomical and functional changes[11-15] . However, studies
regarding the use of these investigations in detecting
ethambutol toxicity are limited, and their results sometimes
conflicting[11,14-17] . Our study thus aims to evaluate the role of
optic function tests, OCT and PVEP in the early detection of
ocular ethambutol toxicity.
SUBJECTS AND METHODS
This study was conducted inthe Ophthalmology Clinic of
Hospital Universiti Sains Malaysia, Kelantan, Malaysia, after
obtaining approval from the Human Research Ethics
Committee of Universiti Sains Malaysia.
The inclusion criteria was all patients aged 18y and above who
were referred to the eye clinic for assessment prior to starting
anti tuberculosis medication, which included treatment with
ethambutol at a dose of 15mg / kg preday. All patients were
also on isoniazid, rifampicin and pyrazinamide treatment as
part of the DOTS strategy. Patients with ocular or neurological
problems which could have affected PVEP findings were
excluded. We also excluded patients with impaired drug
metabolism, such as those with renal or hepatic disease.
Informed consent was obtained from all patients.
A complete history taking and eye examination was performed
in all patients by a single investigator. The ocular examination
included visual acuity, refraction, color vision using Ishihara
plates, assessment of light brightness and red saturation (by
comparing them between eyes ), slit lamp examination,
pupillary examination and funduscopy. The visual field was
assessed using Humphrey visual field 24 - 2 ( Carl Zeiss,
Germany).
The OCT and electrophysiological tests were performed by a
single, trained operator. OCT, which uses low - coherence
interferometry to measure the thickness of the retinal nerve
fibre layer, was done using a Spectral - Domain Heidelberg
Spectralis OCT. PVEP, which is based on detection of an
electrical potential in response to a stimulus in the visual
field, was performed based on the ISCEV PVEP protocol
2009, using a Granzfield PVEP Roland-Consult, RETI-port
32, Germany. Standard silver-silver chloride skin electrodes
were placed based on the “10-20 International System冶. The
stimuli used was a checkerboard with large 1毅(i. e. 60min of
arc) and small 0. 25毅 (15min of arc) checks. PVEP was
tested monocularly in each eye of a single patient, with
appropriate refractive correction. All examinations were
performed immediately prior to commencement of anti -
tuberculosis treatment and repeated 3mo later.
Data was analyzed using Statistical Package for the Social
Sciences IBM Version 22. 0 (SPSS Inc. Chicago, IL, USA).
Paired t-test was used to compare the differences in the optic
nerve function, OCT and PVEP parameters pre and post
ethambutol treatment.
RESULTS
A total number of 72 eyes of 36 patients were examined. The
patients from this study were all Malays from Kelantan,
ranging from 18 to 72y of age, with the median age of 40y.
There were 22 males (61. 1% ) and 14 females (38郾 9% ).
Among these patients, 19 ( 52. 8% ) had no medical
comorbidities; of the remainder, 7 ( 19. 4% ) had
hypertension, while 5 (13. 9% ) had diabetes mellitus. The
majority (94. 4% ) were non smokers.
During the course of this study, none of these 36 patients had
ocular complaints. Clinically, there were also no anterior or
posterior segment changes in all these patients. Pre and post
treatment, there were no changes in visual acuity among these
patients. There was also no relative afferent pupillary defect.
Red saturation, light brightness and colour vision pre and post
3mo of ethambutol treatment remained unaffected.
Table 1 shows the comparison of the visual field mean
deviation before initiation of ethambutol treatment and 3mo
after it. There was a statistically significant deterioration from
pre-treatment values (P=0. 010).
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Table 1摇 Comparison of visual field mean deviation of a paired sample n=72
Parameters Mean (SD) Mean difference (95% CI) t-statisticsa(dt) P
Pre-treatment
Post-treatment
-0. 88 (1. 73)
-1. 07 (1. 78)
-0. 19(-0. 34, -0. 05) -2. 66 (71) 0. 010
aPaired t-test was applied.
Table 2摇 Comparison of retinal nerve fiber layer thickness of a paired sample n=72
Parameters Mean (SD) Mean difference (95% CI) t-statisticsa(dt) P
Superior RNFL
摇 Pre- treatment
摇 Post- treatment
132. 85(9. 17)
134. 42(8. 16)
1. 57 (0. 59, 2. 55) 3. 18 (71) 0. 002
Inferior RNFL
摇 Pre- treatment
摇 Post- treatment
126. 58(14. 87)
128. 83(14. 88)
2. 25 (1. 22, 3. 28) 4. 37 (71) <0. 001
Nasal RNFL
摇 Pre- treatment
摇 Post- treatment
79. 36(9. 03)
81. 18(8. 07)
1. 82 (1. 10, 2. 54) 5. 01 (71) <0. 001
Temporal RNFL
摇 Pre- treatment
摇 Post- treatment
74. 96(8. 92)
80. 49(10. 41)
5. 53 (4. 20,6. 86) 8. 30 (71) <0. 001
aPaired t-test was applied; RNFL: Retinal never fiber layer.
Table 3摇 Comparison PVEP latency and amplitude of a paired sample n=72
Parameters Mean (SD) Mean difference (95% CI) t-statisticsaa(dt) P
P100 latency (1毅)
摇 Pre- treatment
摇 Post- treatment
102. 40 (2. 81)
119. 35 (13. 93)
16. 94(13. 64, 20. 25) 10. 23 (71) <0. 001
P100 latency (0. 25毅)
摇 Pre- treatment
摇 Post- treatment
114. 32 (3. 04)
128. 07 (10. 81)
13. 75(11. 04, 16. 46) 10. 11 (71) <0. 001
P100 amplitude (1毅)
摇 Pre- treatment
摇 Post- treatment
11. 75 (3. 00)
10. 91 (3. 12)
-0. 83(-1. 12, -0. 55) -5. 92 (71) <0. 001
P100 amplitude (0. 25毅)
摇 Pre- treatment
摇 Post- treatment
13. 30 (3. 50)
12. 06 (3. 59)
-1. 24(-1. 75, -0. 74) -4. 90 (71) <0. 001
aPaired t-test was applied.
OCT showed an overall statistically significant increase in the
RNFL after 3mo of ethambutol treatment ( P < 0. 05). The
changes were strongly significant in the inferior, nasal and
temporal quadrants (P<0. 001) (Table 2) .
The PVEP showed significant differences pre and post
ethambutol treatment. Prior to treatment, all PVEP values
were normal, while post-treatment, there were abnormalities
in P100 peak latency and amplitude.
The P100 peak latency showed significant delay (P<0. 001)
with both the large (1毅) and small (0. 25毅) checkered box
stimuli post - treatment. Likewise, the P100 amplitude was
reduced compared to prior to treatment (Table 3) .
DISCUSSION
Tuberculosis is a disease that poses a global problem[18-19] .
With the emergence of drug - resistant tuberculosis strains,
tuberculosis has become increasingly difficult to treat. In
2014, 9. 6 million people worldwide contracted tuberculosis,
and 1. 5 million of them died[20] . The morbidity and mortality
caused by this disease necessitates effective treatment
strategies. WHO has recommended a regime of medications,
which, in combination, have proven useful in the management
of this disease[3] . Unfortunately, as with all drugs, patients
and clinicians have to be aware of potential medication side
effects.
Ethambutol hydrochloride, a butanol derivative, is a main
player in the treatment of tuberculosis[21-22] . It has been
postulated to cause toxic optic neuropathy by the production of
its metabolite, ethylene diaminobutyric acid[21] . The latter
causes transformation of metal ions into chelating agents, thus
leading to decreased levels of copper, iron, and other metals
associated with the mitochondrial cytochromes[23] . Paramount
among its effects is chelation of the copper irons of cytochrome
C oxidase within optic nerve axons, causing depletion of
copper levels[21,24] . Without sufficient copper, cytochrome C
7002
Int Eye Sci, Vol. 17, No. 11, Nov. 2017摇 摇 http: / / ies. ijo. cn
Tel:029鄄82245172摇 85263940摇 摇 Email:IJO. 2000@163. com
oxidase is unable to transport the electrons needed for ATP
production. The decreased ATP levels cause a decrease in
axonal transport of mitochondria, leading to a vicious cycle of
energy depletion and subsequent axonal swelling[25] . Other
mechanisms by which ethambutol is hypothesized to cause
toxicity are demyelination of the visual pathway[7] and
neutralization of lysosomes, resulting in impaired
autophagy[26] .
Since the 1960蒺s, when ethambutol was still an experimental
drug in tuberculosis treatment, monitoring for drug toxicity has
been via visual function tests. Reduced red saturation has
been cited as the earliest clinically detectable parameter of
optic nerve dysfunction in ethambutol toxicity[27] . In our
study, although none of the participants had clinically
significant abnormalities in optic nerve function, the visual
field showed deterioration of the mean deviation, suggesting
progression of optic nerve damage. This is in line with the
changes we observed in the RNFL and PVEP.
Previous studies have documented both increased and
decreased RNFL thickness in the OCT of patients on
ethambutol[11-12,15,28-29] . As discussed earlier, ethambutol
toxicity results in copper chelation, resulting in disruption of
axonal transport to the mitochondria. This process causes
energy depletion and later development of axonal swelling,
which explains the increase in RNFL thickness in the early
stages. However, as the disease progresses, the initial
swelling reduces and is followed by thinning and necrosis of
the papilomacular bundle due to apoptosis, manifesting as
RNFL thinning[30] .
Electrophysiological tests have been used in various studies to
diagnose ethambutol toxicity[11-12] . PVEP is an
electrophysiological test used to detect electrical potentials that
occur in the cortex after visual stimulation with checkered box
stimulus of specific sizes. It is particularly specific for
assessing optic nerve function in the anterior pre - chiasmal
region. As reported in several other studies, the early stages
of toxic optic neuropathy are characterized by delay in PVEP
P100 latency and reduction in its amplitude, prior to detection
of optic nerve dysfunction[11-12] . Latency represents a
prolonged time in milliseconds for the stimulus observed by
the patient蒺s eye to reach and be processed by the brain, and
is usually abnormal in demyelinating conditions. Amplitude in
turns reflects the integrity of the visual pathway, and is
affected by axonal damage. The changes detected on PVEP
are related to the pathophysiology explained earlier.
In view of the statistically significant changes in OCT, which
concur with the results of previous research[14,31-32], we
postulate that the changes in OCT and PVEP are subclinical
early signs of ethambutol toxicity. However, one limitation of
our study is that our tuberculosis patients were all on a multi-
drug regimen, which included isoniazid. This medication has
also been implicated in toxic optic neuropathy, and may thus
act as a confounder[33] . Regardless, our study demonstrates
that toxic optic neuropathy manifests with changes in RNFL
thickness and prolonged P100 peak latency and decreased
amplitude, prior to development of clinical optic nerve
dysfunction.
Ethambutol toxicity is a known complication of tuberculosis
treatment. Optic nerve function tests have traditionally been
used to monitor for signs of toxicity; however, by the time
visual impairment occurs, optic nerve damage may be
irreversible. The use of OCT to detect RNFL thickness and
PVEP to assess P100 latency and amplitude may allow
detection of subclinical anatomical and visual function changes
secondary to ethambutol toxicity, prior to development of
abnormalities on conventional optic nerve function tests.
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